Show simple item record

dc.contributor.authorTrad, MA
dc.contributor.authorNaughton, W
dc.contributor.authorYeung, A
dc.contributor.authorMazlin, L
dc.contributor.authorO'sullivan, M
dc.contributor.authorGilroy, N
dc.contributor.authorFisher, DA
dc.contributor.authorStuart, RL
dc.date.accessioned2017-02-28T21:51:44Z
dc.date.available2017-02-28T21:51:44Z
dc.date.issued2016-11-11
dc.date.submitted2016-12-05
dc.identifier.citationEbola Virus Disease: An Update On Current Prevention and Management Strategies. 2016, 86:5-13 J. Clin. Virol.en
dc.identifier.issn1873-5967
dc.identifier.pmid27893999
dc.identifier.doi10.1016/j.jcv.2016.11.005
dc.identifier.urihttp://hdl.handle.net/10144/618818
dc.description.abstractEbola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virologyen
dc.titleEbola Virus Disease: An Update On Current Prevention and Management Strategiesen
dc.identifier.journalJournal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virologyen
dc.internal.reviewer-noteWrote to first author Traden
refterms.dateFOA2019-03-04T13:12:48Z
html.description.abstractEbola virus disease (EVD) is characterised by systemic viral replication, immuno-suppression, abnormal inflammatory responses, large volume fluid and electrolyte losses, and high mortality in under-resourced settings. There are various therapeutic strategies targeting EVD including vaccines utilizing different antigen delivery methods, antibody-based therapies and antiviral drugs. These therapies remain experimental, but received attention following their use particularly in cases treated outside West Africa during the 2014-15 outbreak, in which 20 (80%) out of 25 patients survived. Emerging data from current trials look promising and are undergoing further study, however optimised supportive care remains the key to reducing mortality from EVD.


Files in this item

Thumbnail
Name:
Trad MA et al - 2016 - Ebola ...
Size:
558.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record